Chronic Pain News and Research

RSS

EpiCept 2010 fourth quarter net loss is $0.06 per share

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2010, and provided an update on its key business initiatives.

24 Feb 2011

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

BioDelivery Sciences International, Inc. announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.

18 Feb 2011

Research: 75% of nonmilitary group medically evacuated for nonbattle injuries did not return to field

After analyzing data on 2,155 private contractors, diplomats and other civilians supporting war efforts in Iraq and Afghanistan who were medically evacuated out of combat zones, researchers have found they are more likely to be evacuated for noncombat-related injuries, but more likely to return to work in-country after treatment for these conditions.

15 Feb 2011

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Zogenix, Inc. announced today the completion of enrollment in its pivotal Phase 3 efficacy study (Study 801) of ZX002. ZX002 is a novel, oral, single-entity, controlled-release formulation of hydrocodone for the treatment of moderate to severe pain in patients requiring around-the-clock opioid therapy for an extended period of time.

10 Feb 2011

Mallinckrodt receives FDA approval for Fentanyl Transdermal System patch ANDA

Covidien, a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for its Fentanyl Transdermal System (FTS) patch. Covidien is the largest supplier of controlled pain medications in the United States based on number of prescriptions.

10 Feb 2011

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

EpiCept Corporation today announced positive results from a Phase IIb trial evaluating the efficacy and safety of EpiCept NP-1 in chemotherapy-induced peripheral neuropathy. EpiCept NP-1 is a topical analgesic cream containing two FDA-approved drugs, amitriptyline and ketamine, in development for the relief of pain from various peripheral neuropathies.

7 Feb 2011

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Accidental damage to thin or buried nerves during surgery can have severe consequences, from chronic pain to permanent paralysis. Scientists at the University of California, San Diego School of Medicine may have found a remedy: injectable fluorescent peptides that cause hard-to-see peripheral nerves to glow, alerting surgeons to their location even before the nerves are encountered.

6 Feb 2011

Ameritox makes significant strides to advance its industry leadership position

Ameritox, the nation's leader in pain medication monitoring, made significant strides to advance its industry leadership position by strengthening the company's commitment to physicians and patients in the past twelve months.

5 Feb 2011

Waismann Method examines link between chronic pain and Opioid-Induced Hyperalgesia

Results from a recent study issued by the Substance Abuse & Mental Health Services Administration revealed that treatment admissions for prescription painkiller abuse rose 345 percent over a 10 year period extending from 1998 to 2008.

5 Feb 2011

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

OXIS International, today announced highly favorable final results from an initial clinical study to assess the beneficial effects of its patent-pending ERGOFLEX joint health formula, launched commercially in December 2010.

1 Feb 2011

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

New research has been published indicating that patients suffering from a painful complication of diabetes may experience a significant improvement in their pain as measured by a pain intensity scale when using an investigational pain medication.

29 Jan 2011

Research sheds light on role of helping in addiction recovery

Participating in community service activities and helping others is not just good for the soul; it has a healing effect that helps alcoholics and other addicts become and stay sober, a researcher from Case Western Reserve University School of Medicine reports.

29 Jan 2011

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

A drug called etanercept can restore responsiveness to the pain-relieving effects of morphine in rats that have developed morphine tolerance, reports a study in the February issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society.

29 Jan 2011

Study identifies gaps in primary health care for seniors with multiple chronic conditions

The number of health care services seniors use is determined more by the number of chronic conditions they have than by their age, according to a new study from the Canadian Institute for Health Information.

28 Jan 2011

Scientists discover new mechanism neurons use to fine-tune electrical output

Scientists in the Hotchkiss Brain Institute at the Faculty of Medicine, University of Calgary, have discovered a new mechanism that nerve cells (neurons) use to fine-tune their electrical output. The exciting discovery, published this week in the prestigious journal Nature Neuroscience, provides new insights about how the activity of the nervous system is regulated at the cellular level.

27 Jan 2011

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

Diamyd completed screening for US Phase III study in type 1 diabetes. The screening of patients for the US Phase III study, DiaPrevent, was completed, ending the recruitment campaign. More than 310 recently diagnosed type 1 diabetes patients between 10 and 20 years of age had, at the completion of screening, been enrolled in the study and received their first injection of the antigen-based therapy Diamyd® or placebo.

25 Jan 2011

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

The medical device company cerbomed cooperated with the Clinic for Psychiatry and Psychotherapy of the University of Regensburg 2010 on a randomized, controlled study into somatosensory pain processing. The study, lead by Prof. Dr. Peter Eichhammer and Dr. Volker Busch, aimed to judge the pain-relieving effect of transcutaneous Vagus Nerve Stimulation (t-VNS).

25 Jan 2011

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory approval from the Australian Therapeutic Goods Administration (TGA) of its Athena™ programmer, a deep brain stimulation (DBS) therapy management system.

24 Jan 2011

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

BioDelivery Sciences International, Inc. today responded to a process patent infringement lawsuit filed and recently served against the Company and certain co-defendants by MonoSol Rx, LLC. The purpose in responding at this time is for BDSI to strongly refute MonoSol's claims and to assure BDSI stockholders that the Company remains focused on vigorously progressing its pipeline and not allowing this claim to present a distraction.

24 Jan 2011

Anaesthetising an arm affects brain activity and rapidly impairs body perception

An Inserm research team in Toulouse, led by Dr Stein Silva (Inserm Unit 825 "Brain imaging and neurological handicaps"), working with the "Modelling tissue and nociceptive stress" Host Team (MATN IFR 150), were interested in studying the illusions described by many patients under regional anaesthetic.

20 Jan 2011

Chronic Pain News and Research

EpiCept 2010 fourth quarter net loss is $0.06 per share

BDSI announces over 50% enrolled in BEMA Buprenorphine Phase 3 study in chronic pain

Research: 75% of nonmilitary group medically evacuated for nonbattle injuries did not return to field

Zogenix completes enrollment in ZX002 Phase 3 study in opioid-experienced adults with moderate to severe pain

Mallinckrodt receives FDA approval for Fentanyl Transdermal System patch ANDA

Positive results from EpiCept NP-1 Phase IIb trial in patients with CPN

Study: Fluorescent probe may serve as useful tool in future surgeries to repair injured nerves

Ameritox makes significant strides to advance its industry leadership position

Waismann Method examines link between chronic pain and Opioid-Induced Hyperalgesia

Highly favorable final results from ERGOFLEX initial clinical study for joint pain relief

Phase III study shows tapentadol ER relieves chronic pain associated with DPN

Research sheds light on role of helping in addiction recovery

Etanercept can restore responsiveness to pain-relieving effects of morphine: Study

Study identifies gaps in primary health care for seniors with multiple chronic conditions

Scientists discover new mechanism neurons use to fine-tune electrical output

Diamyd Medical reports first quarter group total net sales of MSEK 144.5

New study on pain-relieving effect of transcutaneous Vagus Nerve Stimulation

St. Jude Medical's Athena programmer DBS system receives Australian TGA approval

BDSI refutes MonoSol's patent infringement claims relating to BEMA Buprenorphine

Anaesthetising an arm affects brain activity and rapidly impairs body perception

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News